Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY24.77 CNY
Change Today 0.00 / 0.00%
Volume 0.0
600671 On Other Exchanges
As of 3:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

hangzhou tian-mu-shan phar-a (600671) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/18/15 - CNY35.20
52 Week Low
01/15/15 - CNY13.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HANGZHOU TIAN-MU-SHAN PHAR-A (600671)

Related News

No related news articles were found.

hangzhou tian-mu-shan phar-a (600671) Related Businessweek News

No Related Businessweek News Found

hangzhou tian-mu-shan phar-a (600671) Details

Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd manufactures and distributes pharmaceuticals, healthcare products, and medical equipment in China. The company offers its pharmaceutical products in the form of granules, eye drops, soft capsules, oral liquids, tablets, pills, capsules, and others. Its products include Pearl eyesight drops, Dendrobium soft capsules, Ho created capsules, Fule particles, Xianzhuli liquid compounds, and Lily solid gold liquids, as well as Liuweidihuang oral liquid products, such as peppermint oil, menthol, etc. The company is also involved in the biological products manufacture and distribution; food distribution; technology development; investment management; and other activities. Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd was founded in 1958 and is based in Lin'an City, China.

Founded in 1958

hangzhou tian-mu-shan phar-a (600671) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hangzhou tian-mu-shan phar-a (600671) Key Developments

Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Half of 2015

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd reported earnings results for the first half of 2015. Basic loss per share was CNY 0.0458 and negative weighted average return on net assets was 7.3488%.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Board Meeting, Aug 19, 2015

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Board Meeting, Aug 19, 2015. Agenda: To discuss and approve the semi-annual report of 2015; and to consider the proposal of improving renovation project and changing project budget for Tiangong Building.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report First Half, 2015 Results on Aug 20, 2015

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that they will report first half, 2015 results on Aug 20, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600671:CH CNY24.77 CNY 0.00

600671 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600671.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600671 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.6x
Price/Book 40.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANGZHOU TIAN-MU-SHAN PHAR-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at